Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EBIT (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of EBIT data on record, last reported at -$45.5 million in Q4 2023.

  • For Q4 2023, EBIT fell 57.14% year-over-year to -$45.5 million; the TTM value through Dec 2023 reached -$191.1 million, down 226.83%, while the annual FY2025 figure was -$219.9 million, 11.66% down from the prior year.
  • EBIT reached -$45.5 million in Q4 2023 per CGEM's latest filing, down from -$45.2 million in the prior quarter.
  • Across five years, EBIT topped out at $239.7 million in Q2 2022 and bottomed at -$62.8 million in Q1 2023.
  • Average EBIT over 4 years is -$10.5 million, with a median of -$28.2 million recorded in 2022.
  • The widest YoY moves for EBIT: up 1543.5% in 2022, down 2480.25% in 2022.
  • A 4-year view of EBIT shows it stood at -$29.2 million in 2020, then decreased by 17.74% to -$34.3 million in 2021, then rose by 15.72% to -$28.9 million in 2022, then plummeted by 57.14% to -$45.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for EBIT were -$45.5 million in Q4 2023, -$45.2 million in Q3 2023, and -$37.6 million in Q2 2023.